

PTO/SB/08A (07-06)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/713,787		
		Filing Date	November 13, 2003		
		First Named Inventor	Hofland, Hans		
		Art Unit	1615		
		Examiner Name	Gollamudi S. Kishore		
Sheet	1	of	2	Attorney Docket Number	020681-000410US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
W	1	US 5,639,468	06-17-1997	Rodgers et al.	
	2	US 5,652,261	07-29-1997	Ismail	
	3	US 5,654,337	08-05-1997	Roentsch et al.	
	4	US-3,558,690	01-26-1971	Sallmann et al.	
	5	US-4,016,100	04-05-1977	Suzuki et al.	
	6	US-4,089,801	05-16-1978	Schneider	
	7	US-4,235,871	11-25-1980	Papahadjopoulos et al.	
	8	US-4,485,054	11-27-1984	Mezei et al.	
	9	US-4,761,288	08-02-1988	Mezei	
	10	US-5,374,661	12-20-1994	Bellach, II	
	11	US-5,552,157	09-03-1996	Yagi et al.	
	12	US-5,565,213	10-15-1996	Nakamori et al.	
	13	US-5,567,434	10-22-1996	Szoka et al.	
	14	US-5,738,868	04-14-1998	Shinkarenko	
	15	US-5,738,869	04-14-1998	Fischer et al.	
	16	US-5,756,482	05-26-1998	Roberts et al.	
	17	US-5,783,422	06-09-1998	Lichtenberger et al.	
W	18	US-5,795,587	08-18-1998	Gao et al.	



FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
W	19	EP	372527	A1	06-13-1990	Altergon S.A.		<input type="checkbox"/>
W	20	PC	WO 00/29103	A1	05-25-2000	Optime Therapeutics, Inc.		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	4/07
--------------------	--	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60994962 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/713,787
				Filing Date	November 13, 2003
				First Named Inventor	Hofland, Hans
				Art Unit	1615
				Examiner Name	Gollamudi S. Kishore
Sheet	2	of	2	Attorney Docket Number	020681-000410US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	21	BANGHAM <i>et al.</i> , "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids," <i>J. Mol. Biol.</i> , 13:238-252 (1965)	<input type="checkbox"/>	
	22	BARENHOLZT <i>et al.</i> , "A New Method for Preparation of Phospholipid Vesicles (Liposomes) - French Press," <i>FEBS Lett.</i> , 99(1):210-214 (1979)	<input type="checkbox"/>	
	23	BATZRI <i>et al.</i> , "Single bilayer liposomes prepared without sonication," <i>Biochimica et Biophysica Acta</i> , 298:1015-1019 (1973)	<input type="checkbox"/>	
	24	DAVIES, "Biopharmaceutical Considerations in Topical Ocular Drug Delivery," <i>Clin. Exp. Pharmacol. Physiol.</i> , 27:558-562 (2000)	<input type="checkbox"/>	
	25	DEAMER <i>et al.</i> , "Large Volume Liposomes by an Ether Vaporization Method," <i>Biochimica et Biophysica Acta</i> , 443:629-634 (1976)	<input type="checkbox"/>	
	26	KIM <i>et al.</i> , "Preparation of Multivesicular Liposomes," <i>Biochimica et Biophysica Acta</i> , 728:339-348 (1983)	<input type="checkbox"/>	
	27	LE BOURLAIS <i>et al.</i> , "Ophthalmic Drug Delivery Systems--Recent Advances," <i>Progress in Retinal and Eye Research</i> , 17(1):33-58 (1998)	<input type="checkbox"/>	
	28	LE BOURLAIS <i>et al.</i> , "Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study," <i>J. Microencap.</i> , 14(4):457-467 (1997)	<input type="checkbox"/>	
	29	PAPAHADJOPOULOS <i>et al.</i> , "Phospholipid Model Membranes," <i>Biochimica et Biophysica Acta</i> , 135:624-638 (1967)	<input type="checkbox"/>	

Examiner Signature	Kishore	Date Considered	4/07
--------------------	---------	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.